Proteomic analysis of the in vivo EL4 TCL model. (A) Schematic representation of the in vivo TCL model and the proteomic workflow used to obtain samples for proteomic analysis. Venn diagrams illustrate the total number of proteins identified in bulk tumors under respective treatments (n = 3 per group). (B-C) Venn diagrams of the EL4 tumor proteomics analysis displaying significantly upregulated and downregulated proteins in tumors from BexT4+Cile-treated mice compared with those from Veh-treated mice. (D) Heat map derived from the proteomic differential expression analysis. Only selected proteins of interest related to angiogenesis, cell migration, metabolism, immune response, cellular transport, and cell proliferation and survival that were identified as significantly upregulated or downregulated are shown. (E) TF enrichment analysis was performed using gene set enrichment analysis of the differentially expressed proteins among paired BexT4+Cile and Veh samples. The plot shows TF pathways that are significantly upregulated (red) or downregulated (blue) in BexT4+Cile vs Veh tumors (false discovery rate of <25% and P value < .05%). FC, fold change.